Research programme: HIV/AIDS therapeutic lentivirus - American Gene Technologies

Drug Profile

Research programme: HIV/AIDS therapeutic lentivirus - American Gene Technologies

Alternative Names: AG 1105; AG1105 - AIDS therapeutics lentivirus; AGT 103

Latest Information Update: 04 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator American Gene Technologies International
  • Developer American Gene Technologies International; University of Maryland, Baltimore
  • Class Antivirals; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 12 Oct 2017 American Gene Technologies International plans to file an IND application with the US FDA in USA for HV infection in the first quarter of 2018
  • 14 Mar 2017 American Gene Technologies plans a phase I trial of AGT 103 for HIV infection in USA in 2018 (Parenteral)
  • 14 Mar 2017 GeoVax enters into collaboration with American Gene Technologies for the development of a functional cure for HIV infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top